Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know
A systematic review highlights often-overlooked heart and lung complications in blood cancers, calling for closer collaboration between hematology and cardiology.
This Semin Hematol review synthesises evidence on both thrombotic and non-thrombotic (heart failure, pulmonary hypertension) cardiovascular complications in MPN, highlighting their prognostic impact and the need for cardio-hematology collaboration. It identifies guideline-directed HF therapy and antithrombotic management as areas requiring MPN-specific consideration.
What the study was
- Study design
- Narrative review
- Population
- MPN patients (ET, PV, MF) with cardiovascular complications
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Semin Hematol
Why it surfaced
Practical clinical review in Semin Hematol highlighting underrecognised CV burden in MPN — useful hematologist-facing educational content. No new primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.